Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics disclosed inducement equity grants to Chief Medical Officer Jing Marantz, awarded October 26, 2026, under its 2024 Inducement Plan. The grants include options on 275,061 shares at an $11.26 exercise price and RSUs covering 199,822 shares, vesting over three years subject to continued service.
Key figures
- Rsu shares
- 199822
- Options shares
- 275061
- Options exercise price
- 11.26
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.